Browse Technologies
Keyword Search
Oncology
Search Results
Displaying: 11 - 18 of 18 Results
A system for in vivo generation of protective CD8+ T lymphocytes and other cells of hematopoietic origin
Differentiated CD8+ effector T cells mediate long-term immunity and protection against infectious diseases and cancer. Naive T cells are refractory to transduction with viral vectors without extensive ex vivo manipulations. A team of researchers at…
Investigators
- Arlene Sharpe
- Nicholas Haining
Potent OGT inhibitors for the treatment of cancer and diabetic complications
First-in-class and potent OGT inhibitors The Walker group has developed novel high throughput assays (HTS) and screened 200,000 compounds at the Institute for Chemistry and Cell Biology (ICCB) at Harvard Medical School, and identified several…
Investigators
- Suzanne Walker Kahne
- Michael Lazarus
- Benjamin Gross
Knockout mouse model for human liver cancer
While most hepatocytes in healthy liver are resting cells, deletion of Mad2 in liver activates the cell cycles and causes proliferation of hepatocytes. Cre-mediated, simultaneous liver-specific knockout of Mad2 and p53 induces mouse cancer which…
Investigators
- Peter Sorger
- Ying Yue
Small-molecule macrocycles: Potent and selective Src kinase inhibitors
Macrocyclic compounds have unique properties that allow them to cover regions of chemical space not addressed by other small-molecule structural classes. By performing an in vitro selection screen of a broad untargeted DNA-encoded library of 13,824…
Investigators
- David Liu
- Ralph Kleiner
Mass spectrometry-based in vitro kinome activity assay
This technology is a new generation, high-throughput assay to quantitatively assess the activity of the kinome in a variety of samples. Cocktails of synthetic peptides are combined with a sample of interest and phosphorylated by kinases in the…
Investigators
- Steven Gygi
- Judit Villen
- Kazuishi Kubota
- Yong Yu
Trioxacarcins and analogs: DNA-modifying compounds with potent anti-proliferative effects
The trioxacarcins are a new class of DNA-modifying natural products with potent antiproliferative effects (with subnanmolar IC70 values against lung, mammary, and CNS cancer cell lines). Trioxacarcin A, B, and C were first discovered and isolated…
Investigators
- Andrew Myers
- Jakub Svenda
- Nicholas Hill
- Robert Yu
- Daniel Smaltz
- Thomas Magauer
Fzd2 - novel anti-cancer therapeutic target
The role of β-catenin accumulation in the development of tumorigenicity has been well documented to date, with various mutations in β-catenin, APC, and axin genes typically to blame. Although β-catenin accumulation plays a role in hepatocellular…
Investigators
- Gavin MacBeath
- Taran Gujral
Controlled delivery of TLR agonists in structural polymeric devices
Scientist at the Mooney lab demonstrated that three different types of pathogens could be incorporated to act as adjuvant in cancer vaccines. They have successfully incorporated three Toll-like receptor agonists (TLR) within a structural polymeric…
Investigators
- David Mooney
- Omar Ali
- Glenn Dranoff